SCG Cell Therapy Pte. Ltd. has acquired rights to human induced pluripotent stem cell technology from Singapore’s Agency for Science, Technology and Research (A*STAR)’s Accelerate Technologies Pte. Ltd. to support the development of natural killer (NK) cell therapies for leukemia, liver cancer, gastric cancer and other solid tumors.
Digital health company Connectedhealth Pte. Ltd. launched its Sugosure system to offer care management to type 2 diabetes patients in Singapore. The system is aiming to tackle the “poor management” of type 2 diabetes with technology and to reduce the risk of long-term complications, said Ronald Ling, the CEO of Connectedhealth.
Researchers at the Peter Doherty Institute for Infection and Immunity, the University of Queensland, Griffith University, the University of Adelaide and St. Jude Children's Research Hospital have unlocked a key to making existing front-line antibiotics work again against Streptococcuspneumoniae, the bacteria that cause pneumonia.
Prism Biolab Co. Ltd. has added Genentech Inc., a unit of Roche Holding AG, to the list of users for its peptide mimetic small-molecules library after signing a multitarget research collaboration and licensing agreement.
Inveniai LLC and Kyowa Kirin Co. Ltd. have expanded their partnership a second time, inking their most recent multiple drug discovery agreement. The multiyear deal will see the duo discover novel targets and treatments for therapeutic areas across Kyowa Kirin’s portfolio and areas of interest using Inveniai’s artificial intelligence (AI) platform.
Two med-tech giants GE Healthcare Ltd. and Boston Scientific Corp. are teaming up to expand cardiac care in Southeast Asia. GE Healthcare and Boston Scientific reported plans to collaborate on an end-to-end cardiac care solution offered to cardiac care centers in Southeast Asia. The suite of care offered ranges from diagnostic to percutaneous coronary intervention.
Computational technology and high-quality data will help scientists to improve R&D and find better treatments for human diseases, according to experts at the Wuxi Global Forum 2022.
In vitro diagnostic (IVD) company Virtue Diagnostics (Suzhou) Co. Ltd. has raised $100 million in a series B round to develop its clinical diagnostics and bring them to other markets. “With the latest funding, Virtue Diagnostics will hire talent, introduce technology, and expand to other markets,” said Johnson Zhang, CEO of Virtue Diagnostics.
Prism Biolab Co. Ltd. has added Genentech Inc., a unit of Roche Holding AG, to the list of users for its peptide mimetic small-molecules library after signing a multitarget research collaboration and licensing agreement. Under the agreement, Tokyo-based Prism Biolab will open its Pepmetics Library, a library of peptide mimetic small molecules, to screen against targets selected by Roche and Genentech.
Inveniai LLC and Kyowa Kirin Co. Ltd. have expanded their partnership a second time, inking their most recent multiple drug discovery agreement. The multiyear deal will see the duo discover novel targets and treatments for therapeutic areas across Kyowa Kirin’s portfolio and areas of interest using Inveniai’s artificial intelligence (AI) platform.
RSS
